Annual Report Details $185M ATM Program, $48.2M Phase 3 Trial Commitment, and Significant Losses

summarizeSummary

Inhibikase Therapeutics' annual report reveals a net loss of $48.26 million for 2025, a strong cash position of $178.8 million, and details a $185 million ATM program. The company also committed $48.2 million to its pivotal Phase 3 clinical study for IKT-001 in PAH.

check_boxKey Events

• Annual Financial Results

  Reported a net loss of $48.26 million for the fiscal year ended December 31, 2025, an increase from $27.52 million in 2024, with an accumulated deficit of $142.7 million.

• Strong Liquidity Position

  Maintained cash, cash equivalents, and marketable securities totaling $178.8 million as of December 31, 2025, projected to fund operations for at least the next twelve months.

• Significant Capital Raises

  Successfully raised approximately $107.6 million in net proceeds from an underwritten public offering in November 2025 and $99.6 million from a private placement in October 2024.

• Large At-The-Market (ATM) Program

  Established an ATM program in June 2025 to sell up to $185 million in common stock, with $3.0 million already sold in February 2026.

auto_awesomeAnalysis

This annual 10-K filing provides comprehensive financial results and strategic updates for Inhibikase Therapeutics. While the initiation of the Phase 3 study and the net loss were previously announced on the same day, this report offers critical details on the company's financial health, capital structure, and significant investments in its lead drug candidate. The substantial cash position provides a runway for operations, but the increased net loss and the large At-The-Market (ATM) program highlight ongoing capital needs and potential future dilution. The significant commitment to the Phase 3 trial through a large CRO contract underscores the company's focus on advancing IKT-001.